Key Highlights
● Chemomab Therapeutics has agreed to merge with private precision-medicine firm Scipher Medicine, redirecting its anti-CCL24 antibody nebokitug from a liver-disease pipeline toward an AI-guided Phase 2 rheumatoid arthritis trial, backed by a $30 million private placement and a targeted fourth-quarter 2026 close.
● As of December 31, 2025, Chemomab reported cash, equivalents, and short-term deposits of $10.4 million, down from $14.3 million a year earlier.
● The deal leaves legacy Chemomab holders with a minority roughly 32% stake and contingent value rights whose value depends on milestones not yet defined in detail.
● Investors should watch for merger closing progress and initial data from the AI-guided Phase 2 rheumatoid arthritis trial.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a small-cap Israeli biotech that has spent years developing nebokitug (formerly CM-101), an anti-CCL24 monoclonal antibody, for the rare liver disease primary sclerosing cholangitis (PSC), announced on July 8, 2026 that it will merge with privately held Scipher Medicine, a precision-medicine company known for its CMS-approved rheumatoid arthritis (RA) treatment-response test, PrismRA. The stock-for-stock deal, paired with a $30 million private placement, would create a combined company renamed Scipher Medicine Corporation, expected to trade under a new ticker, and would refocus nebokitug's near-term clinical priority toward an AI-guided Phase 2 trial in rheumatoid arthritis rather than the liver indication where Chemomab had built its clinical case.
What happened
Under the announced terms, existing Chemomab shareholders would hold approximately 32% of the combined, fully diluted company, with Scipher shareholders holding roughly 68%. Chemomab holders would also receive contingent value rights (CVRs) tied to future nebokitug milestones. The transaction is structured around a pre-money valuation of $150 million and is accompanied by a concurrent $30 million private placement from a syndicate that Chemomab identified as being led by Northpond Ventures, with participation from Khosla Ventures, Blue Owl Healthcare Opportunities, and funds managed by Neuberger, among other investors. The combined entity would be led by Scipher's current chief executive, Dr. Reginald Seeto, with Chemomab co-founder and CEO Dr. Adi Mor joining the board. Closing is targeted for the fourth quarter of 2026, subject to shareholder votes, SEC registration of the new securities, and a corporate redomiciling.
Why the development matters
The merger materially changes the investment thesis for CMMB shareholders. Rather than advancing nebokitug through a newly clarified Phase 3 pathway in PSC, a plan the FDA had endorsed only months earlier, the combined company intends to prioritize an AI-guided Phase 2 trial in rheumatoid arthritis, using Scipher's PrismRA multi-omic signature test to select patients likely to respond. That pivot trades a defined, near-term regulatory pathway in a rare disease for a larger but more competitive and historically difficult indication: management noted that no fundamentally new RA mechanism has reached approval since 2012, and no new branded RA drug since 2019. For existing shareholders, the trade-off is a smaller ownership stake and milestone-contingent CVRs in exchange for a materially longer cash runway and a shot at a much larger commercial market.
Company and product background
Nebokitug is a first-in-class antibody that blocks the chemokine CCL24, targeting both inflammation and fibrosis. Its clinical proof-of-concept comes from the Phase 2 SPRING trial in PSC, a 76-patient, 33-site study published in the American Journal of Gastroenterology on December 2, 2025. The trial met its primary safety and tolerability endpoint through 48 weeks, with no notable safety signals, and showed secondary biomarker signals, including a statistically significant reduction in liver stiffness at 15 weeks among patients with moderate-to-advanced fibrosis, alongside numerical improvements in ELF score and PRO-C3. On March 19, 2026, Chemomab reported that an FDA End-of-Phase 2 meeting had produced alignment on a single pivotal Phase 3 design for PSC, with a primary endpoint based on time-to-first clinical event; the program also carries FDA and EMA orphan drug designations and FDA Fast Track status. Chemomab has separately said it is evaluating additional indications, including systemic sclerosis, where nebokitug has shown preclinical signals, though no clinical timeline has been disclosed. Under the pending merger, near-term clinical priority shifts to RA, with a Phase 2 topline readout targeted for H1 2028; the fate of the PSC Phase 3 program within the combined company has not been detailed in the releases reviewed.
Financial position
As of December 31, 2025, Chemomab reported cash, equivalents, and short-term deposits of $10.4 million, down from $14.3 million a year earlier, with full-year 2025 R&D expense of $5.8 million (down from $11.3 million in 2024), G&A expense of $3.7 million, and a net loss of $9.0 million, versus $13.9 million in 2024. Shares outstanding rose 52% year over year to roughly 575.4 million ordinary shares (about 7.19 million ADSs), reflecting prior dilutive financings. By the first-quarter 2026 update, cash had declined to approximately $8.0 million, with a runway cited into 2027. The pending $30 million placement, combined with Scipher's resources, is expected to extend pro forma runway into the second half of 2028, though the merger's roughly 68/32 share split represents substantial additional dilution for current CMMB holders, layered on top of the historical dilution already reflected in share count growth.
Bull case
Proponents would point to a meaningfully extended cash runway, a large syndicate of specialist healthcare investors backing the $30 million raise, and access to an AI-driven patient-selection platform that could improve trial economics in a market Chemomab's own materials size at roughly $24 billion in the U.S., with over 20 million RA patients worldwide and roughly a third of current patients failing to reach low disease activity on existing therapies. Nebokitug's PSC data already demonstrated a favorable safety profile and biologically plausible anti-fibrotic activity, which bulls could argue supports its mechanism carrying over to RA. PrismRA additionally offers a revenue-generating, CMS-approved diagnostic business, though no specific revenue figures were disclosed in the reviewed materials.
Risk case
Skeptics would note the deal leaves legacy Chemomab holders with a minority ~32% stake and CVRs whose value depends on milestones not yet defined in detail. The pivot away from PSC comes just months after the company touted FDA alignment on a streamlined Phase 3 pathway there, raising questions about capital-allocation continuity and whether prior PSC-specific investment will be monetized. The merger requires shareholder and regulatory approvals and could be delayed or fail to close. RA is a crowded therapeutic category with a long history of high-profile clinical failures, and nebokitug has no RA-specific clinical data yet. CMMB shares carry the volatility typical of a micro-cap biotech, with a market capitalization near $11 million as of late July 2026.
What investors should watch next
1. Filing and shareholder-vote timing for the merger (proxy/S-4 registration).
Conclusion
The Scipher merger reshapes Chemomab from a single-indication liver-disease developer into a minority stakeholder in a broader, AI-enabled rheumatology and diagnostics company, trading near-term dilution and strategic uncertainty for a longer runway and a larger addressable market. Whether that trade benefits current shareholders will depend heavily on deal execution, the undisclosed CVR terms, and early data from a rheumatoid arthritis program that does not yet have clinical results of its own.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.






Please wait processing your request...